ABIVAX Société Anonyme 0RA9.L Stock
ABIVAX Société Anonyme Price Chart
ABIVAX Société Anonyme 0RA9.L Financial and Trading Overview
| ABIVAX Société Anonyme stock price | 13.78 EUR |
| Previous Close | 15.3 EUR |
| Open | 15.86 EUR |
| Bid | 0 EUR x 0 |
| Ask | 0 EUR x 0 |
| Day's Range | 15.86 - 16.16 EUR |
| 52 Week Range | 5.68 - 19.58 EUR |
| Volume | 227 EUR |
| Avg. Volume | 21.8K EUR |
| Market Cap | 1.48M EUR |
| Beta (5Y Monthly) | 1.321072 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.47 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0RA9.L Valuation Measures
| Enterprise Value | 674.22M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 14.83578 |
| Price/Book (mrq) | 41.435898 |
| Enterprise Value/Revenue | 6742.232 |
| Enterprise Value/EBITDA | -11.957 |
Trading Information
ABIVAX Société Anonyme Stock Price History
| Beta (5Y Monthly) | 1.321072 |
| 52-Week Change | 46.31% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 19.58 EUR |
| 52 Week Low | 5.68 EUR |
| 50-Day Moving Average | 15.23 EUR |
| 200-Day Moving Average | 9.36 EUR |
0RA9.L Share Statistics
| Avg. Volume (3 month) | 21.8K EUR |
| Avg. Daily Volume (10-Days) | 27.93K EUR |
| Shares Outstanding | 9.98M |
| Float | 17.5M |
| Short Ratio | N/A |
| % Held by Insiders | 2.46% |
| % Held by Institutions | 50.57% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -56646.00000000000000000000000000000000% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -38.54% |
| Return on Equity (ttm) | -315.23% |
Income Statement
| Revenue (ttm) | 100K EUR |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 100K EUR |
| EBITDA | -56388668 EUR |
| Net Income Avi to Common (ttm) | -69846000 EUR |
| Diluted EPS (ttm) | -2.47 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 26.95M EUR |
| Total Cash Per Share (mrq) | 0.64 EUR |
| Total Debt (mrq) | 46.07M EUR |
| Total Debt/Equity (mrq) | 529.43 EUR |
| Current Ratio (mrq) | 1.719 |
| Book Value Per Share (mrq) | 0.39 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -65579000 EUR |
| Levered Free Cash Flow (ttm) | -51252376 EUR |
Profile of ABIVAX Société Anonyme
| Country | United Kingdom |
| State | N/A |
| City | Paris |
| Address | 7-11 boulevard Haussmann |
| ZIP | 75009 |
| Phone | 33 1 53 83 08 41 |
| Website | https://www.abivax.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 22 |
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that modulate the body's natural immune system to treat patients with chronic inflammatory, infectious, and cancer diseases. The company's products include obefazimod that is in Phase III clinical trials for the treatment of ulcerative colitis; Phase IIb clinical trials for the treatment of Crohn's Disease; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and in a pre-clinical trial for the treatment of Respiratory Syncytial Virus. It also develops ABX 196, an immune enhancer candidate that is in Phase 2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue, influenza, and respiratory syncytial virus. It has license agreement with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Q&A For ABIVAX Société Anonyme Stock
What is a current 0RA9.L stock price?
ABIVAX Société Anonyme 0RA9.L stock price today per share is 13.78 EUR.
How to purchase ABIVAX Société Anonyme stock?
You can buy 0RA9.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ABIVAX Société Anonyme?
The stock symbol or ticker of ABIVAX Société Anonyme is 0RA9.L.
How many shares does ABIVAX Société Anonyme have in circulation?
The max supply of ABIVAX Société Anonyme shares is 91.81K.
What is ABIVAX Société Anonyme Price to Earnings Ratio (PE Ratio)?
ABIVAX Société Anonyme PE Ratio is now.
What was ABIVAX Société Anonyme earnings per share over the trailing 12 months (TTM)?
ABIVAX Société Anonyme EPS is -2.47 EUR over the trailing 12 months.